Drug Trial Radar · NCT00468845
Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy
Last checked: Nov 20, 2026Latest source record: Feb 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Jun 2007
Primary completion
May 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 25 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.
Conditions
- Pain, Postoperative
Interventions
pregabalin (Lyrica)Drug
150 mg/day double blind (divided doses)
pregabalin (Lyrica)Drug
300 mg/day double blind (divided doses)
matched placeboDrug
matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)Time frame: Day 2 (24 hours post surgery [PS])
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Glendale, California
Pfizer Investigational Site
Pasadena, California
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Philadelphia, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Prague, Czechia
Pfizer Investigational Site
Kowloon, Hong Kong
Pfizer Investigational Site
Shatin, Hong Kong
Pfizer Investigational Site
Parktown, South Africa
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa
Pfizer Investigational Site
Krugersdorp, Gauteng, South Africa
Pfizer Investigational Site
Pretoria, Gauteng, South Africa
Pfizer Investigational Site
Ladysmith, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Newcastle, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Cape Town, Western Cape, South Africa
Pfizer Investigational Site
Cadiz, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Valencia, Spain
Pfizer Investigational Site
Lund, Sweden
Pfizer Investigational Site
Örebro, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
Bangkoknoi, Bangkok, Thailand
Pfizer Investigational Site
Muang, Changwat Khon Kaen, Thailand
Pfizer Investigational Site
Muang, Chiang Mai, Thailand
Pfizer Investigational Site
Birmingham, United Kingdom
Pfizer Investigational Site
Liverpool, United Kingdom
Pfizer Investigational Site
Livingstone, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.